StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%

Tarsus Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Tarsus Pharmaceuticals's price to sales ratio was 5.5× on Nov 11, 2026, against 9.3× a year earlier. Over the last 5 years it ranged from 4.7× to 74.9×, with a median of 12.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20265.5×−4.0
2025Dec 31, 20259.5×−6.8
2024Dec 31, 202416.3×−30.3
2023Dec 29, 202346.6×+22.4
2022Dec 30, 202224.2×+16.0
2021Dec 31, 20218.2×–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?